UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 342

Sortiert nach

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors

Genes & cancer, 2017-05, Vol.8 (3-4), p.497-504

2017

Volltextzugriff (PDF)

Identification of Circulating Long Noncoding RNA HOTAIR as a Novel Biomarker for Diagnosis and Monitoring of Non–Small Cell Lung Cancer

Technology in cancer research & treatment, 2017-12, Vol.16 (6), p.1060-1066

2017

Volltextzugriff (PDF)

Infratemporal Fossa Metastasis of Non-Small-Cell Lung Adenocarcinoma: A Case Report and Literature Review

Ear, nose, & throat journal, 2024-01, p.1455613231218139-1455613231218139

2024

Volltextzugriff (PDF)

Impact of analgesia on cancer recurrence and mortality within 5 years after stage I non-small cell lung cancer resection

Tumori, 2022-08, Vol.108 (4), p.364-370

2022

Volltextzugriff (PDF)

Prevention and management of acute esophageal toxicity during concomitant chemoradiotherapy for locally advanced lung cancer

Tumori, 2022-10, Vol.108 (5), p.470-476

2022

Volltextzugriff (PDF)

NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma

Genes & cancer, 2014-07, Vol.5 (7-8), p.293-302

2014

Volltextzugriff (PDF)

Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241231260-17588359241231260

2024

Volltextzugriff (PDF)

Helical Image-guided Stereotactic Body Radiotherapy (SBRT) for the Treatment of Earlystage Lung Cancer: A Single-institution Experience at the Willis-Knighton Cancer Center

Tumori, 2014-01, Vol.100 (1), p.42-48

2014

Volltextzugriff (PDF)

Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study

Therapeutic advances in medical oncology, 2024, Vol.16, p.17588359231221907-17588359231221907

2024

Volltextzugriff (PDF)

Long-Term Oncologic Outcomes for Patients Undergoing Volatile Versus Intravenous Anesthesia for Non-Small Cell Lung Cancer Surgery: A Retrospective Propensity Matching Analysis

Cancer control, 2018-01, Vol.25 (1), p.1073274818775360-1073274818775360

2018

Volltextzugriff (PDF)

Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer

Tumor biology, 2024-03, Vol.46 (s1), p.S269-S281

2024

Volltextzugriff (PDF)

Correlation analysis of EGFR gene mutation abundance and the efficacy of targeted therapy with osimertinib in nonsmall cell lung cancer-a case control study

Journal of oncology pharmacy practice, 2024-01, p.10781552231224372-10781552231224372

2024

Volltextzugriff (PDF)

PD-L1 expression testing in non-small cell lung cancer

Therapeutic Advances in Medical Oncology, 2018-01, Vol.10, p.1758835918763493-1758835918763493

2018

Volltextzugriff (PDF)

Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer

Technology in Cancer Research & Treatment, 2018-01, Vol.17, p.1533033818782788

2018

Volltextzugriff (PDF)

Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy

Therapeutic Advances in Medical Oncology, 2018-01, Vol.10, p.1758835918789364-1758835918789364

2018

Volltextzugriff (PDF)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)

Therapeutic advances in medical oncology, 2018-01, Vol.10, p.1758834017745012-1758834017745012

2018

Volltextzugriff (PDF)

LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis

International journal of immunopathology and pharmacology, 2019, Vol.33, p.2058738419859699-2058738419859699

2019

Volltextzugriff (PDF)

Fishing for ALK with immunohistochemistry may predict response to crizotinib

Tumori, 2013-09, Vol.99 (5), p.e229-e232

2013

Volltextzugriff (PDF)

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Therapeutic advances in medical oncology, 2021, Vol.13, p.1758835920980558-1758835920980558

2021

Volltextzugriff (PDF)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

Therapeutic Advances in Medical Oncology, 2021, Vol.13, p.1758835921992968-1758835921992968

2021

Volltextzugriff (PDF)

ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

Therapeutic Advances in Medical Oncology, 2016-01, Vol.8 (1), p.32-47

2016

Volltextzugriff (PDF)

Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241229435-17588359241229435

2024

Volltextzugriff (PDF)

Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241234504-17588359241234504

2024

Volltextzugriff (PDF)

Assessment of efficacy and safety of MET tyrosine kinase inhibitors in non-small-cell lung cancer patients with MET alterations

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241248352-17588359241248352

2024

Volltextzugriff (PDF)

Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non–small cell lung cancer patients

Experimental biology and medicine (Maywood, N.J.), 2023-02, Vol.248 (4), p.361-369

2023

Volltextzugriff (PDF)

1 – 25 von 342

Suche als RSS-Feed

Aktive Filter

KollektionSage Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(339)
Mit Volltextzugriff
(339)

Publikationsform

Artikel
(342)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(316)
Science & Technology
(316)
Nsclc
(259)
Oncology
(259)
Lung Cancer
(251)
Humans
(213)
Carcinoma, Non-Small-Cell Lung - Pathology
(122)
Female
(117)
Lung Neoplasms - Pathology
(113)
Male
(113)
Cancer Research
(108)
Biomedicine
(105)
Non-Small Cell Lung Carcinoma
(105)
Middle Aged
(104)
Biomedical And Life Sciences
(102)
Carcinoma, Non-Small-Cell Lung - Genetics
(101)
Small Cell Lung Carcinoma
(94)
Lung Neoplasms - Genetics
(85)
Aged
(82)
Prognosis
(72)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

SAGE Complete
(342)
EZB Free E-Journals
(292)
MEDLINE
(213)
IngentaConnect
(141)
Journals@Ovid Complete
(117)
Springer Nature - Complete Springer Journals
(111)
Single Journals
(61)
IngentaConnect Journals
(17)
Elsevier ScienceDirect Journals Complete
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors

Identification of Circulating Long Noncoding RNA HOTAIR as a Novel Biomarker for Diagnosis and Monitoring of Non–Small Cell Lung Cancer

Infratemporal Fossa Metastasis of Non-Small-Cell Lung Adenocarcinoma: A Case Report and Literature Review

Impact of analgesia on cancer recurrence and mortality within 5 years after stage I non-small cell lung cancer resection

Prevention and management of acute esophageal toxicity during concomitant chemoradiotherapy for locally advanced lung cancer

NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma

Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology

Helical Image-guided Stereotactic Body Radiotherapy (SBRT) for the Treatment of Earlystage Lung Cancer: A Single-institution Experience at the Willis-Knighton Cancer Center

Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study

Long-Term Oncologic Outcomes for Patients Undergoing Volatile Versus Intravenous Anesthesia for Non-Small Cell Lung Cancer Surgery: A Retrospective Propensity Matching Analysis

Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer

Correlation analysis of EGFR gene mutation abundance and the efficacy of targeted therapy with osimertinib in nonsmall cell lung cancer-a case control study

PD-L1 expression testing in non-small cell lung cancer

Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer

Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)

LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis

Fishing for ALK with immunohistochemistry may predict response to crizotinib

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study

Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy

Assessment of efficacy and safety of MET tyrosine kinase inhibitors in non-small-cell lung cancer patients with MET alterations

Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non–small cell lung cancer patients

Aktive Filter

Suchergebnisse filtern